A familial case of pseudohypoaldosteronism type II (PHA2) with a novel mutation (D564N) in the acidic motif in WNK4.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
06 2019
Historique:
received: 25 12 2018
revised: 28 03 2019
accepted: 07 04 2019
pubmed: 3 5 2019
medline: 27 5 2020
entrez: 3 5 2019
Statut: ppublish

Résumé

There have been still few case reports of pseudohypoaldosteronism type II (PHA2), also known as Gordon's syndrome, genetically diagnosed, and this is the first report of familial PHA2 case in Japan with a novel D564N mutation in WNK4. A 29-year-old woman was admitted to our hospital due to hyperkalemia (serum potassium: 6.4 mmol/L). She had mild hypertension (135/91 mm Hg), a bicarbonate level at the lower limit of the normal range (HCO Genetic analysis revealed that the patient and her mother had a novel missense mutation (D564N) in the acidic motif in WNK4, which leads to the diagnosis of PHA2. Administration of trichlormethiazide (1 mg/day) effectively ameliorated her blood pressure (114/69 mm Hg), plasma bicarbonate (25 mmol/L), serum potassium (4.3 mmol/L), and urinary calcium excretion (27.2 mg/g Cre). We report the first Japanese familial case of PHA2 with WNK4 mutation. D564N mutation in WNK4 is a novel genetic cause of PHA2 with a relatively mild phenotype.

Sections du résumé

BACKGROUND
There have been still few case reports of pseudohypoaldosteronism type II (PHA2), also known as Gordon's syndrome, genetically diagnosed, and this is the first report of familial PHA2 case in Japan with a novel D564N mutation in WNK4.
METHODS
A 29-year-old woman was admitted to our hospital due to hyperkalemia (serum potassium: 6.4 mmol/L). She had mild hypertension (135/91 mm Hg), a bicarbonate level at the lower limit of the normal range (HCO
RESULTS
Genetic analysis revealed that the patient and her mother had a novel missense mutation (D564N) in the acidic motif in WNK4, which leads to the diagnosis of PHA2. Administration of trichlormethiazide (1 mg/day) effectively ameliorated her blood pressure (114/69 mm Hg), plasma bicarbonate (25 mmol/L), serum potassium (4.3 mmol/L), and urinary calcium excretion (27.2 mg/g Cre).
CONCLUSION
We report the first Japanese familial case of PHA2 with WNK4 mutation. D564N mutation in WNK4 is a novel genetic cause of PHA2 with a relatively mild phenotype.

Identifiants

pubmed: 31044551
doi: 10.1002/mgg3.705
pmc: PMC6565545
doi:

Substances chimiques

Antihypertensive Agents 0
Diuretics 0
Protein Serine-Threonine Kinases EC 2.7.11.1
WNK4 protein, human EC 2.7.11.1
Trichlormethiazide Q58C92TUN0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e705

Informations de copyright

© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Références

Mol Genet Genomic Med. 2019 Jun;7(6):e705
pubmed: 31044551
J Clin Endocrinol Metab. 2004 Aug;89(8):4025-30
pubmed: 15292344
Endocrinology. 2010 Apr;151(4):1829-36
pubmed: 20181799
Pediatrics. 1982 Mar;69(3):317-24
pubmed: 7063287
Science. 2001 Aug 10;293(5532):1107-12
pubmed: 11498583
Cell Rep. 2013 Mar 28;3(3):858-68
pubmed: 23453970
Cell Metab. 2007 May;5(5):331-44
pubmed: 17488636
Pediatr Nephrol. 1987 Jul;1(3):473-8
pubmed: 2978968
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
J Clin Endocrinol Metab. 2002 Jul;87(7):3248-54
pubmed: 12107233
Metabolism. 1979 Aug;28(8):831-42
pubmed: 454520
Clin Exp Pharmacol Physiol. 2001 Dec;28(12):1048-52
pubmed: 11903313
Clin Exp Nephrol. 2017 Feb;21(1):63-75
pubmed: 26920127
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Nature. 2012 Jan 22;482(7383):98-102
pubmed: 22266938
Nat Genet. 2006 Oct;38(10):1124-32
pubmed: 16964266
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Am J Physiol Renal Physiol. 2007 Feb;292(2):F545-54
pubmed: 17018846
Hypertension. 2005 Aug;46(2):295-300
pubmed: 15998707
Australas Ann Med. 1970 Nov;19(4):287-94
pubmed: 5490655
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Nat Genet. 2012 Mar 11;44(4):456-60, S1-3
pubmed: 22406640
Arch Intern Med. 1978 Apr;138(4):607-10
pubmed: 637641

Auteurs

Takashi Sakoh (T)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Akinari Sekine (A)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Takayasu Mori (T)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Hiroki Mizuno (H)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Masahiro Kawada (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Rikako Hiramatsu (R)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Eiko Hasegawa (E)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Noriko Hayami (N)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Masayuki Yamanouchi (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Tatsuya Suwabe (T)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Naoki Sawa (N)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Yoshifumi Ubara (Y)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.

Takuya Fujimaru (T)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Eisei Sohara (E)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Uchida Shinichi (U)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Junichi Hoshino (J)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.

Kenmei Takaichi (K)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH